Details of Drug Interaction | MecDDI

Drug General Information (ID: DDICQIWDLK)
Drug Name			Butalbital		Drug Info		Warfarin		Drug Info
Drug Type		Small molecule				Small molecule
Therapeutic Class		Analgesics				Anticoagulants
Structure

Mechanism of Butalbital-Warfarin Interaction (Severity Level: Major)
CYP450 enzyme induction Click to Show/Hide Mechanism Graph

Drug Name		Butalbital				Warfarin
Mechanism		CYP450 3A4 inducer				CYP450 3A4 substrate
Key Mechanism Factor 1
		Factor Name		Cytochrome P450 3A4				× Structure Sequence MALIPDLAMETWLLLAVSLVLLYLYGTHSHGLFKKLGIPGPTPLPFLGNILSYHKGFCMFDMECHKKYGKVWGFYDGQQPVLAITDPDMIKTVLVKECYSVFTNRRPFGPVGFMKSAISIAEDEEWKRLRSLLSPTFTSGKLKEMVPIIAQYGDVLVRNLRREAETGKPVTLKDVFGAYSMDVITSTSFGVNIDSLNNPQDPFVENTKKLLRFDFLDPFFLSITVFPFLIPILEVLNICVFPREVTNFLRKSVKRMKESRLEDTQKHRVDFLQLMIDSQNSKETESHKALSDLELVAQSIIFIFAGYETTSSVLSFIMYELATHPDVQQKLQEEIDAVLPNKAPPTYDTVLQMEYLDMVVNETLRLFPIAMRLERVCKKDVEINGMFIPKGVVVMIPSYALHRDPKYWTEPEKFLPERFSKKNKDNIDPYIYTPFGSGPRNCIGMRFALMNMKLALIRVLQNFSFKPCKETQIPLKLSLGGLLQPEKPVVLKVESRDGTVSGA
		Gene Name		CYP3A4
		Uniprot ID		CP3A4_HUMAN
		KEGG Pathway		hsa:1576
		Protein Family		Cytochrome P450 family
		Protein Function		A cytochrome P450 monooxygenase involved in the metabolism of sterols, steroid hormones, retinoids and fatty acids (PubMed:10681376, PubMed:11093772, PubMed:11555828, PubMed:14559847, PubMed:12865317, PubMed:15373842, PubMed:15764715, PubMed:20702771, PubMed:19965576, PubMed:21490593, PubMed:21576599). Mechanistically, uses molecular oxygen inserting one oxygen atom into a substrate, and reducing the second into a water molecule, with two electrons provided by NADPH via cytochrome P450 reductase (NADPH--hemoprotein reductase). Catalyzes the hydroxylation of carbon-hydrogen bonds (PubMed:2732228, PubMed:14559847, PubMed:12865317, PubMed:15373842, PubMed:15764715, PubMed:21576599, PubMed:21490593). Exhibits high catalytic activity for the formation of hydroxyestrogens from estrone (E1) and 17beta-estradiol (E2), namely 2-hydroxy E1 and E2, as well as D-ring hydroxylated E1 and E2 at the C-16 position (PubMed:11555828, PubMed:14559847, PubMed:12865317). Plays a role in the metabolism of androgens, particularly in oxidative deactivation of testosterone (PubMed:2732228, PubMed:15373842, PubMed:15764715, PubMed:22773874). Metabolizes testosterone to less biologically active 2beta- and 6beta-hydroxytestosterones (PubMed:2732228, PubMed:15373842, PubMed:15764715). Contributes to the formation of hydroxycholesterols (oxysterols), particularly A-ring hydroxylated cholesterol at the C-4beta position, and side chain hydroxylated cholesterol at the C-25 position, likely contributing to cholesterol degradation and bile acid biosynthesis (PubMed:21576599). Catalyzes bisallylic hydroxylation of polyunsaturated fatty acids (PUFA) (PubMed:9435160). Catalyzes the epoxidation of double bonds of PUFA with a preference for the last double bond (PubMed:19965576). Metabolizes endocannabinoid arachidonoylethanolamide (anandamide) to 8,9-, 11,12-, and 14,15-epoxyeicosatrienoic acid ethanolamides (EpETrE-EAs), potentially modulating endocannabinoid system signaling (PubMed:20702771). Plays a role in the metabolism of retinoids. Displays high catalytic activity for oxidation of all-trans-retinol to all-trans-retinal, a rate-limiting step for the biosynthesis of all-trans-retinoic acid (atRA) (PubMed:10681376). Further metabolizes atRA toward 4-hydroxyretinoate and may play a role in hepatic atRA clearance (PubMed:11093772). Responsible for oxidative metabolism of xenobiotics. Acts as a 2-exo-monooxygenase for plant lipid 1,8-cineole (eucalyptol) (PubMed:11159812). Metabolizes the majority of the administered drugs. Catalyzes sulfoxidation of the anthelmintics albendazole and fenbendazole (PubMed:10759686). Hydroxylates antimalarial drug quinine (PubMed:8968357). Acts as a 1,4-cineole 2-exo-monooxygenase (PubMed:11695850). Also involved in vitamin D catabolism and calcium homeostasis. Catalyzes the inactivation of the active hormone calcitriol (1-alpha,25-dihydroxyvitamin D(3)) (PubMed:29461981). Click to Show/Hide
Mechanism Description		Increased metabolism of Warfarin caused by Butalbital mediated induction of CYP450 enzyme

Recommended Action
Management		Close attention should be paid to alterations in coagulation if a patient must take both drugs and for several weeks after the dose of the barbiturate is changed or discontinued. alternatively, a benzodiazepine might be used instead of a barbiturate, if appropriate. Patients should be advised to promptly report any signs of blood clots (e.g. chest pain, shortness of breath, sudden loss of vision, or pain, redness or swelling in an extremity).

References
1	Aggeler PM, O'Reilly RA "Effect of heptabarbital on the response to bishydroxycoumarin in man." J Lab Clin Med 74 (1969): 229-38. [PMID: 4184022]
2	Antlitz AM, Tolentino M, Kosai MF "Effect of butabarbital on orally administered anticoagulants." Curr Ther Res Clin Exp 10 (1968): 70-3. [PMID: 4967727]
3	Blouin R, Chaudhary I, Nishihara K, Cox S "The effects of liver and renal disease on stereoselective serum binding of flurbiprofen." Br J Clin Pharmacol 35 (1993): 62-4. [PMID: 8448071]
4	Cucinell SA, Conney AH, Sansur M, Burns JJ "Drug interactions in man. I: lowering effect of phenobarbital on plasma levels of bishydroxycoumarin (dicumarol) and diphenylhydantoin (dilantin)." Clin Pharmacol Ther 6 (1965): 420-9. [PMID: 14314964]
5	Elin RJ, Ruddel M, Korn WR, Thompson BC "Discrepant results for determination of theophylline in serum from a patient with renal failure ." Clin Chem 29 (1983): 1870. [PMID: 6616853]
6	Goss JE, Dickhaus DW "Increased bishydroxycoumarin requirements in patients receiving phenobarbital." N Engl J Med 273 (1965): 1094-5. [PMID: 4158082]
7	Ku LL, Ward CO, Durgin SJ "A clinical study of drug interaction and anticoagulant therapy." Drug Intell Clin Pharm 4 (1970): 300-6.
8	MacDonald MG, Robinson DS "Clinical observations of possible barbiturate interference with anticoagulation." JAMA 204 (1968): 97-100. [PMID: 5694725]
9	O'Reilly RA, Trager WF, Motley CH, Howald W "Interaction of secobarbital with warfarin pseudoracemates." Clin Pharmacol Ther 28 (1980): 187-95. [PMID: 7398186]
10	Clark NP, Hoang K, Delate T, Horn JR, Witt DM. Warfarin Interaction With Hepatic Cytochrome P-450 Enzyme-Inducing Anticonvulsants.?Clin Appl Thromb Hemost. 2018;24(1):172-178. [PMID: 28118749]
11	Scaroni C, Mazzoni PL, D'Amico E, Benvenuti C, Hind ID "Pharmacokinetics of oral and rectal flurbiprofen in children." Eur J Clin Pharmacol 27 (1984): 367-9. [PMID: 6510467]
12	Wells PS, Holbrook AM, Crowther NR, Hirsh J "Interactions of warfarin with drugs and food." Ann Intern Med 121 (1994): 676-83. [PMID: 7944078]